APA

Biron P., Durand M., Roché H., Delozier T., Battista C., Fargeot P., Spaeth D., Bachelot T., Poiget E., Monnot F., Tanguy M. L. & Curé H. (20080811). Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. : Bone marrow transplantation.

Chicago

Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy M L and Curé H. 20080811. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. : Bone marrow transplantation.

Harvard

Biron P., Durand M., Roché H., Delozier T., Battista C., Fargeot P., Spaeth D., Bachelot T., Poiget E., Monnot F., Tanguy M. L. and Curé H. (20080811). Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. : Bone marrow transplantation.

MLA

Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy M L and Curé H. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. : Bone marrow transplantation. 20080811.